days tier the mwt of camnary ecckoion. Therefore. the pmribility of reliab!c detection d the early phase of myncardial infarction by using NMR imaging aitbuut the administmtion of contrast agent has been qxstioncd. At preres. etTm?n hnvc been directed toward rk earlier drtectinn of myocardial infarction. with better delinentian and contrn~. hv usine txuamaenetic 113.141 and suoemammaenetir: il51 tiMR Gtitrast a&Is. Delineation of &cted m~wrdius after the administration of NMR contrast agents is also influenced by the time OT imaging aRcr inject& (7.8). Yost oftbe currsntlv availabk NMR cmwast aeeents cause siwsl enhmtcement prrdominantly in normal ~myocardium ;nd static blood adiacent to infarct regions (13.16): distinguishing between my&rdial infarct are~and tbe blood poaimay be pmbkmatic. Magnetic suxcptibiiity-enhancing agents and ruperparamag~tic agents resuh in zi@ rupprcssion in normal myowdium and static blood in the Idl vcntricul~ chamber but not in iahemic regions (14.151. Therefore. they provide dear and pemktent delincntian of regions with occlt!Ld vessels (14.15).
Ik mechanism of signal supprrssion induced by dyspmsium dtihyknctrkmine pmtaacetic acid-bkmethykmidc (DyDl'PA-BMA (g-043 Injection]). but not by supcrparaagelnfrmnenerine~heia~llulnrspaceinrebionothmueh which it rsses (17). The feasibility of using DylYfPA-BMA for demarcatioo cf the area in jeqxmiy IW and for differentiation of occlusive and repaibsed mywudial infarctr (I of ihir agent Detemdnation of -the-lowest ~ive~forpooduci~c*ardelk~~ofthciachemic or ittfated region fa P time sufficknt to acquire NMR Ns is a ptwquisite for clinical applications. ThnfotE, tlte specific aims of the culTen study were 11 to d&e the IV/C! s&ctivc dose of DYDTFA-GA (s-043 Injectica) for delineadlg acutely i&xsd regions; and 2) to assrx.8 and co~xpare the timedewndmt recovery cd signal after intravenous i&&n ot di5erent &s of thk agent in nwmal and acutely infarcted myocardium. as well as skel*al muscle.
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